Scarica l'app Stockscreener
10.99
8.26%
0.82
Dopo l'orario di chiusura:
10.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$10.17
Aprire:
$10.342
Volume 24 ore:
10.21M
Relative Volume:
2.02
Capitalizzazione di mercato:
$2.79B
Reddito:
$885.72M
Utile/perdita netta:
$-457.98M
Rapporto P/E:
-6.1863
EPS:
-1.7765
Flusso di cassa netto:
$293.05M
1 W Prestazione:
+10.10%
1M Prestazione:
+30.92%
6M Prestazione:
+39.02%
1 anno Prestazione:
+25.68%
Intervallo 1D:
$10.00
$11.03
Intervallo di 1 settimana:
$9.515
$11.03
Portata 52W:
$6.00
$11.03
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
10.99 | 2.58B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
16.96 | 53.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.84 | 42.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.65 | 41.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.29 | 31.62B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
563.70 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Ripresa | Evercore ISI | Outperform |
| 2025-10-15 | Ripresa | TD Cowen | Buy |
| 2025-10-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Iniziato | Wedbush | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy |
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Overweight |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight |
| 2018-08-08 | Ripresa | JP Morgan | Overweight |
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Iniziato | Barclays | Equal Weight |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | FBR Capital | Outperform |
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating - marketscreener.com
BCRXBiocryst Pharmaceuticals Inc Volatility & Greeks - Finviz
BioCryst lures 9 new hires with stock awards tied to $9.65 shares - Stock Titan
How Shutting Its Discovery Center To Pursue External Innovation At BioCryst (BCRX) Has Changed Its Investment Story - Sahm
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $16 to $32 - Moomoo
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more - Medical Marketing and Media
BioCryst Pharmaceuticals Inc (BCRX) Stock Up 4.6% and Still Unde - GuruFocus
How (BCRX) Movements Inform Risk Allocation Models - Stock Traders Daily
BCRX Maintained by Cantor Fitzgerald -- Price Target Raised to $29 - GuruFocus
BioCryst to Close Birmingham Research Facility by End of 2026 - WBMA
BioCryst Pharmaceuticals (BCRX) Surges 4.8% as Bullish Volume Lifts Stock Toward Key ResistanceExtension Target - dars.gov.et
BCRX Maintained by HC Wainwright & Co. -- Price Target Stays at $32 - GuruFocus
BioCryst Pharmaceuticals Price Target Maintained With a $32.00/Share by HC Wainwright & Co. - Moomoo
BioCryst winds down internal discovery as it pivots to external innovation - The Pharma Letter
Jefferies raises BioCryst stock price target on R&D shift By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
BioCryst Pharmaceuticals (BCRX) Shifts Focus to External Innovat - GuruFocus
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
BioCryst (BCRX) to Halt Internal Research Programs in Strategic Shift - GuruFocus
BioCryst Refocuses on External Innovation, Winds Down Internal R&D and Closes Birmingham Facility to Accelerate Rare Disease Pipeline Growth – Minichart - Minichart
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs - marketscreener.com
BioCryst to close Alabama research facility, cut costs By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark - marketscreener.com
BioCryst to close Alabama research facility, cut costs - Investing.com
BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub - Stock Titan
BioCryst shuts Birmingham lab, cuts 2026 spending outlook - Stock Titan
BCRX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
Price to earnings forward of BioCryst Pharmaceuticals, Inc. – BX:BO1 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – BX:BO1 - TradingView
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Price to sales forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Price to sales forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Price to book forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
Enterprise value to EBITDA forward of BioCryst Pharmaceuticals, Inc. – TRADEGATE:BO1 - TradingView
Enterprise value to EBIT forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (DUS:BO1) - TradingView
Fierce Biotech Layoff Tracker 2026: BioCryst ends internal programs; Biogen sheds Apellis R&D roles - Fierce Biotech
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:BCRX) - TradingView
BioCryst Pharmaceuticals, Inc. Actuals & Estimates (SWB:BO1) - TradingView
BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level - Yahoo Finance
Biocryst Pharmaceuticals stock hits 52-week high at $10.32 By Investing.com - Investing.com Australia
Biocryst Pharmaceuticals stock hits 52-week high at $10.32 - Investing.com
BioCryst Pharmaceuticals options trading jumps to 13,522 - Investing.com
BioCryst (BCRX) Is Up 11.7% After New HAE Data Spotlight ORLADEYO And Navenibart Potential - Sahm
BioCryst Pharmaceuticals options trading jumps to 13,522 By Investing.com - Investing.com Australia
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals Inc (BCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trading Systems Reacting to (BCRX) Volatility - Stock Traders Daily
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
1.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):